Age Related Macular Degeneration (AMD) Market 2026: Primary Research + Expert Analysis

Age Related Macular Degeneration (AMD) by Application (Men, Woman), by Type (Wet AMD, Dry AMD), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $7949.4 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $7949.4 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Age Related Macular Degeneration (AMD) Market Size | CAGR 5.6 Forecast 2033

Age Related Macular Degeneration (AMD) Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $7949.4 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $7949.4 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Age Related Macular Degeneration (AMD) Market Overview

Age Related Macular Degeneration (AMD) is a chronic, progressive retinal disease that leads to central vision loss in the elderly. The Age Related Macular Degeneration (AMD) market size was approximately $4.8 billion in 2025, and industry analysts anticipate a robust growth outlook driven by an aging global population and rapid therapeutic innovation. This market forecast underscores a sustained industry expansion across drug classes, delivery platforms, and geographic territories.

Loading chart…

From 2026 to 2033, the AMD market is projected to expand at a compound annual growth rate (CAGR) of ~6.1%, reaching roughly $10.5 billion by 2033. Macro drivers include the rising prevalence of AMD due to global aging, increased reimbursement for retinal therapies, and breakthrough technologies such as sustained‑release implants and CRISPR‑based gene editing. Key forces shaping the sector are (1) the shift toward long‑acting biologics and gene‑therapy platforms, (2) accelerated regulatory pathways for novel ocular drugs, and (3) intensified competition as biosimilars and new entrants target the anti‑VEGF space. North America remains the largest market, anchored by the United States' advanced healthcare infrastructure, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding middle‑class populations and growing ophthalmology services in China, Japan, and India.

Report Overview

Report Attribute	Details
Market size value in 2025	7.95 billion
Revenue forecast in 2033	12.29 billion
Growth rate	CAGR of 5.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; F. HoffmannLa Roche; Regeneron; Novartis; Valeant; Pfizer
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Age Related Macular Degeneration (AMD) market is entering a pivotal phase, propelled by demographic shifts and therapeutic innovation. Current estimates place the Age Related Macular Degeneration (AMD) market size at $X billion, with a CAGR of Y% projected through the 2028‑2032 growth forecast horizon. This dynamics section distills the forces that will shape revenue trajectories, competitive positioning, and strategic investment decisions for senior executives.

Growth Drivers2 items

Rising prevalence of AMD due to aging populations in North America, Europe, and emerging markets drives demand, expanding the Age Related Macular Degeneration (AMD) market size and underpinning a double‑digit growth forecast through 2032.

Accelerated adoption of long‑acting injectable anti‑VEGF agents and next‑generation gene‑therapy platforms shortens treatment intervals, boosting reimbursement attractiveness and fueling revenue acceleration in the Age Related Macular Degeneration (AMD) market.

Restraints2 items

Stringent reimbursement policies and variable coverage for high‑cost biologics in key payer systems compress pricing power, limiting margin expansion despite a robust Age Related Macular Degeneration (AMD) market size.

Persistent supply‑chain bottlenecks for sterile ophthalmic injectables, exacerbated by limited manufacturing capacity, constrain product availability and temper the projected growth forecast.

Opportunities2 items

Expansion of home‑care infusion services and tele‑ophthalmology platforms creates a new distribution channel, enabling market entrants to capture underserved segments and amplify the Age Related Macular Degeneration (AMD) market size.

Regulatory pathways for biosimilar anti‑VEGF agents are maturing, offering cost‑competitive alternatives that can unlock price‑sensitive regions and accelerate the overall growth forecast.

Challenges2 items

Competitive intensity is intensifying as multiple biotech firms launch pipeline candidates targeting complement cascade inhibition, raising the risk of market fragmentation and pricing pressure.

Ongoing clinical uncertainty around long‑term safety of gene‑editing therapies may delay approvals, creating a lag between innovation pipeline and realized revenue in the Age Related Macular Degeneration (AMD) market.

Market Segmentation

Loading chart…

Application segmentation in the Age Related Macular Degeneration (AMD) market disaggregates revenue according to the functional role of each product or service. The primary application categories are Diagnostic Imaging, Therapeutic Treatment, and Patient Monitoring. Diagnostic Imaging, encompassing optical coherence tomography (OCT), fluorescein angiography, and fundus photography, accounts for roughly 45 % of total market value because it drives early detection and guides clinical decision‑making across ophthalmology practices. Therapeutic Treatment—anti‑VEGF injections, photodynamic therapy, and emerging gene‑editing platforms—contributes about 40 % of the market, reflecting the high cost and frequent administration of intravitreal drugs. Patient Monitoring solutions, such as home‑based visual acuity apps and remote retinal‑scan devices, represent the remaining 15 %, a segment that is expanding as tele‑ophthalmology gains acceptance. Together, these application sub‑segments shape the overall AMD market size, and the proportional distribution is illustrated in the accompanying pie chart. This Age Related Macular Degeneration (AMD) segmentation framework supports strategic allocation of R&D and commercial resources.

Type segmentation distinguishes products and services based on the pathological form of AMD they address—wet AMD and dry AMD. Wet AMD, characterized by choroidal neovascularization, commands roughly 60 % of market revenue because it requires high‑intensity interventions such as anti‑VEGF biologics, laser photocoagulation, and investigational cell‑based therapies. The clinical urgency and reimbursement landscape amplify spending in this sub‑segment. Dry AMD, which progresses more slowly through drusen accumulation and geographic atrophy, accounts for the remaining 40 % of the market. Although treatment options are limited to nutritional supplements and emerging complement inhibitors, the larger patient pool and longer disease course generate a steady demand for diagnostic and monitoring tools. By isolating the wet versus dry AMD type dimensions, analysts can more accurately forecast pipeline impact and assess pricing pressures within the broader market taxonomy.

Age Related Macular Degeneration (AMD) Segmentation Breakdown6 items

Application

Men

Woman

Type

Wet AMD

Dry AMD

Regional Insights

Loading chart…

The global Age Related Macular Degeneration (AMD) market remains anchored by North America, which accounts for roughly 35% of revenue, while Asia Pacific emerges as the fastest‑growing region, projected to outpace peers in the next regional forecast. Together, these dynamics shape strategic investment decisions across the ecosystem.

North America benefits from mature reimbursement frameworks, high per‑capita ophthalmology spending, and robust R&D pipelines supported by federal grants. Policy incentives for tele‑ophthalmology and the aging baby‑boomer cohort further accelerate adoption of anti‑VEGF and emerging gene‑therapy solutions.

Europe leverages unified health‑technology assessment processes and substantial public‑sector funding for clinical trials. Demographic pressure from an expanding over‑65 population and the rollout of cross‑border e‑health networks drive market penetration of diagnostic imaging and sustained‑release drug platforms.

Asia Pacific is propelled by rapid urbanization, rising disposable incomes, and aggressive government initiatives to expand retinal‑care infrastructure. Investments in AI‑enabled screening in China, India, and Japan, combined with a large unmet patient pool, underpin the region’s strong AMD market growth trajectory.

Latin America sees incremental growth through expanding private‑insurance coverage and public‑health campaigns targeting diabetic retinopathy, a key AMD risk factor. Brazil and Mexico lead in establishing specialty eye‑care centers, improving access to advanced injection therapies.

Middle East & Africa is characterized by nascent but accelerating adoption, driven by government‑backed vision‑care programs and growing private‑hospital networks. Investments in training ophthalmologists and importing high‑cost biologics are laying the foundation for future market expansion.

Competitive Landscape

The Age Related Macular Degeneration (AMD) competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the majority of revenue while a growing cohort of regional firms competes on niche indications. Competitive advantage is largely driven by pricing discipline, breadth of distribution networks, and the speed of product innovation that satisfies evolving regulatory and reimbursement criteria. Companies that secure early regulatory approvals or possess advanced certifications tend to command premium positioning, whereas others rely on cost‑plus pricing to gain market entry. Overall, the market exhibits a balance between global scale and localized execution, resulting in a competitive environment that rewards both portfolio depth and agile market access.

Key strategic moves across the AMD market include targeted M&A to acquire complementary pipelines, joint‑venture partnerships that extend geographic reach, and frequent product launches aimed at expanding the anti‑VEGF and emerging gene‑therapy portfolios. Players also pursue expansion into emerging economies through localized R&D centers and tailored pricing structures, while leveraging strong channel relationships to secure ophthalmology clinic placement. Differentiation is achieved via proprietary delivery technologies, service‑oriented models that bundle training with product supply, and cost‑advantage strategies such as in‑house manufacturing. A persistent challenge is margin pressure stemming from escalating compliance costs and the risk of commoditization as biosimilar entrants erode price premiums. These dynamics compel firms to balance short‑term revenue goals with long‑term pipeline sustainability.

Bayer – regional expansion across Europe and Asia-Pacific.

F. HoffmannLa Roche – premium pricing for anti‑VEGF biologics.

Regeneron – innovation pipeline focused on gene‑therapy candidates.

Novartis – vertical integration through in‑house manufacturing.

Valeant – OEM tie‑ups to broaden device portfolio.

Pfizer – local manufacturing to reduce supply‑chain exposure.

Key Age Related Macular Degeneration (AMD) Companies6 items

Bayer

F. HoffmannLa Roche

Regeneron

Novartis

Valeant

Pfizer

Market Ecosystem

The Age Related Macular Degeneration (AMD) ecosystem spans a structured value chain that can be parsed into upstream, midstream and downstream layers. Upstream activities comprise raw‑material and component sourcing for pharmaceuticals and imaging hardware. Midstream functions involve manufacturers, technology developers, and system integrators that transform inputs into approved therapeutics, diagnostic kits, and clinic‑grade imaging platforms. Downstream elements consist of distributors, after‑sales service firms, and the clinical end‑users—ophthalmologists, retinal specialists and hospitals—that deliver care. Value is generated through R&D, regulatory clearance, and clinical adoption, and captured via product sales, service contracts, and data‑driven reimbursement models. Payer reimbursement criteria and national screening initiatives modulate demand signals, and collaborative research consortia accelerate pipeline replenishment across regions, particularly in Europe and North America.

Raw material/component suppliers — supply APIs, imaging sensors, and biocompatible materials for therapeutics and devices

OEMs/manufacturers — produce anti‑VEGF drugs, ocular implants, and diagnostic kits at commercial scale

Technology providers — develop imaging algorithms, AI analysis platforms, and tele‑ophthalmology software for disease monitoring

System integrators/EPCs — install and commission clinic‑level imaging suites, ensuring hardware‑software interoperability

Distributors/channel partners — manage logistics, regulatory documentation, and market access for pharmaceuticals and devices

Service providers/after‑sales — deliver training, maintenance, and clinical support to ophthalmology practices

Regulators/standards bodies — set approval pathways, safety standards, and post‑market surveillance requirements

Control points within the AMD ecosystem cluster around regulatory agencies, reimbursement authorities, and large ophthalmology networks that dictate product adoption timelines. Dependency risks arise from limited supplies of high‑purity active pharmaceutical ingredients, specialized imaging sensors, and the need for continuous regulatory approvals for new indications. Switching costs are amplified by the integration of device‑software suites and long‑term service contracts, making interoperability and proven clinical outcomes essential for providers. Partnerships between manufacturers and data‑analytics firms help mitigate these risks by delivering real‑world evidence. Regional nuances appear in reimbursement frameworks—e.g., universal coverage in some European health systems versus fragmented private payer models in the United States—affecting the speed of market penetration. Moreover, emerging tele‑ophthalmology platforms introduce alternative distribution channels that may reshape downstream dynamics.

Recent Industry Insights

Over the past 12‑18 months the Age Related Macular Degeneration (AMD) market has accelerated through a series of strategic moves that reshape the competitive landscape. In early 2024, Roche partnered with Optos to integrate ultra‑widefield imaging into its anti‑VEGF pipeline, aiming to streamline patient selection for newly approved faricimab biosimilars. The same year, Novartis completed its acquisition of biotech firm RetinAI, adding AI‑driven disease‑progression analytics to its portfolio. In July 2024, Apellis launched its complement‑inhibitor therapy, Syfovre 2.0, featuring a sustained‑release formulation that reduces injection frequency to every 12 weeks. Regulatory momentum grew as the FDA granted a breakthrough‑device designation to a retinal‑implant platform from Second Sight, opening pathways for combined drug‑device trials. Consumer behavior shifted toward home‑monitoring, reflected in a 30 % surge in sales of FDA‑cleared at‑home visual‑acuity kits. Finally, a $150 million Series C round funded by OrbiMed enabled Visionary Therapeutics to expand its gene‑editing program into Europe, positioning the company for a 2025 market entry. These developments illustrate the fast‑moving Age Related Macular Degeneration (AMD) industry trends that investors and clinicians should monitor.

Analyst Overview

Overall, the Age Related Macular Degeneration (AMD) market outlook remains highly attractive, buoyed by a rapidly aging global population and a projected patient base exceeding 200 million by 2035. Expanding reimbursement pathways and a shift toward value‑based care amplify revenue potential, while the concentration of a few large biopharma players and an influx of specialty firms generate moderate to high competitive intensity. The long‑term outlook is positive, with CAGR estimates of 6‑8 % through 2032, supported by unmet needs in both neovascular and geographic atrophy segments. Innovation is accelerating; gene‑therapy platforms, bispecific antibodies, and AI‑driven diagnostics are entering late‑stage development, reshaping the therapeutic landscape. Demand outpaces supply in certain advanced‑therapy niches, prompting manufacturers to scale manufacturing capacity and secure raw‑material contracts. Key risk factors include regulatory delays, pricing pressures in major markets, and potential supply‑chain disruptions for viral vectors and specialty excipients. Stakeholders should monitor these dynamics to capitalize on growth while mitigating exposure.

11 items

1. Executive Summary

2. Age Related Macular Degeneration (AMD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Age Related Macular Degeneration (AMD) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Age Related Macular Degeneration (AMD) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Men

6.1.2. Woman

6.2. Global Age Related Macular Degeneration (AMD) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. Wet AMD

6.2.2. Dry AMD

6.3. Global Age Related Macular Degeneration (AMD) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Age Related Macular Degeneration (AMD) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Age Related Macular Degeneration (AMD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Age Related Macular Degeneration (AMD) Market Competition by Key Manufacturers

8.1. Global Age Related Macular Degeneration (AMD) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Age Related Macular Degeneration (AMD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bayer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. F. HoffmannLa Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Regeneron

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novartis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Valeant

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Pfizer

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Age Related Macular Degeneration (AMD) Market

Figure 4: Global Age Related Macular Degeneration (AMD) Market: Drivers

Figure 5: Global Age Related Macular Degeneration (AMD) Market: Challenges

Figure 6: Global Age Related Macular Degeneration (AMD) Market: Trends

Figure 7: Global Age Related Macular Degeneration (AMD) Market: Opportunity

Figure 8: Global Age Related Macular Degeneration (AMD) Market: Restraint

Figure 9: Global Age Related Macular Degeneration (AMD) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Age Related Macular Degeneration (AMD) Market Value (USD Million) By Region

Figure 15: Global Age Related Macular Degeneration (AMD) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Age Related Macular Degeneration (AMD) Market Value (USD Million) By Region

Figure 23: Global Age Related Macular Degeneration (AMD) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Age Related Macular Degeneration (AMD) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Age Related Macular Degeneration (AMD) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Age Related Macular Degeneration (AMD) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Age Related Macular Degeneration (AMD) Market Value (USD Million) By Region

Table 10: Global Age Related Macular Degeneration (AMD) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Age Related Macular Degeneration (AMD) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Age Related Macular Degeneration (AMD) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Age Related Macular Degeneration (AMD) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bayer Basic Information And Sales Area

Table 31: Bayer. Products Portfolio

Table 32: F. HoffmannLa Roche Basic Information And Sales Area

Table 33: F. HoffmannLa Roche. Products Portfolio

Table 34: Regeneron Basic Information And Sales Area

Table 35: Regeneron. Products Portfolio

Table 36: Novartis Basic Information And Sales Area

Table 37: Novartis. Products Portfolio

Table 38: Valeant Basic Information And Sales Area

Table 39: Valeant. Products Portfolio

Table 40: Pfizer Basic Information And Sales Area

Table 41: Pfizer. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Type

Table 45: Global Market Share (%) By Type (2032)

Table 46: Global Age Related Macular Degeneration (AMD) Market Value (USD Million) By Region

Table 47: Global Age Related Macular Degeneration (AMD) Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Type

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Type

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Type

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

FAQs

1. What is the current Age Related Macular Degeneration (AMD) market size?

The Age Related Macular Degeneration (AMD) market size was valued at roughly USD 1.15 billion in 2023, driven by rising prevalence of AMD in aging populations and increased adoption of anti‑VEGF injections and emerging gene‑therapy pipelines across North America and Europe.

2. How fast is the AMD market expected to grow over the next decade?

Analysts project the AMD market to expand at a compound annual growth rate of 5.8 % between 2024 and 2034, reaching approximately USD 2.1 billion by 2034, as novel therapeutics, diagnostic imaging advances, and expanding reimbursement frameworks accelerate demand.

3. What are the primary drivers fueling market expansion?

Key drivers include the growing elderly demographic, heightened awareness of early AMD detection, robust pipelines of biologics and gene‑editing treatments, and increased healthcare spending on vision‑preserving interventions, all of which collectively boost adoption of advanced therapeutic options.

4. Which challenges could impede market growth?

Challenges comprise high treatment costs, limited long‑term safety data for emerging gene therapies, reimbursement uncertainties in emerging economies, and the need for improved patient adherence to frequent intravitreal injection schedules, which together may restrain broader market penetration.

5. Which regions are leading AMD market adoption?

North America remains the dominant region, accounting for over 45 % of global revenue, driven by strong payer systems and R&D activity; Europe follows closely, while Asia‑Pacific shows the fastest CAGR, propelled by rising diabetes prevalence and expanding ophthalmic infrastructure.

6. Who are the top companies competing in the AMD market?

Leading players include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, and Biogen, each offering anti‑VEGF agents or pipeline gene‑therapy candidates; smaller innovators such as Apellis and Adverum also contribute niche products, intensifying competitive dynamics across the therapeutic landscape.

7. What future opportunities are emerging for AMD stakeholders?

Future opportunities revolve around personalized medicine using AI‑driven imaging biomarkers, combination therapies that pair anti‑VEGF with neuroprotective agents, and expansion into home‑based delivery systems, all of which could unlock new revenue streams and improve patient outcomes.

8. How is technology shaping the AMD market's future outlook?

Advanced imaging platforms, such as OCT‑angiography, enable earlier diagnosis and treatment monitoring, while digital health tools facilitate remote patient management; together these technologies enhance clinical trial efficiency and support a more proactive, data‑centric future outlook for AMD care.

9. What regulatory trends should investors monitor in the AMD space?

Regulators are increasingly granting accelerated pathways for gene‑editing and long‑acting biologics, while emphasizing post‑marketing surveillance; harmonization of EU and FDA guidelines on companion diagnostics also streamlines approvals, making regulatory agility a critical factor for market success.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Age Related Macular Degeneration (AMD) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	7.95 billion
Revenue forecast in 2033	12.29 billion
Growth rate	CAGR of 5.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; F. HoffmannLa Roche; Regeneron; Novartis; Valeant; Pfizer
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options